Orgenesis Inc

Orgenesis Inc. is a privately held biotechnology company headquartered in Germantown, Maryland. Founded in 2012, the company employs 83 people and generates an annual revenue of $50 million. Orgenesis focuses on developing and commercializing decentralized cell and gene therapies (CGTs). They aim to make these innovative treatments more affordable and accessible to patients worldwide through their POCare Network, a collaboration between academia, hospitals, and industry partners. The company's POCare Services business unit is responsible for establishing and managing decentralized POCare Centers and proprietary OMPULs (Off-the-Shelf Platform for Universal Cell Manufacturing). Orgenesis distinguishes itself by its commitment to advancing CGTs to market through strategic partnerships. Their approach prioritizes a rapid, globally harmonized pathway for these therapies to reach patients efficiently and cost-effectively. The company's decentralized production model seeks to lower costs and increase accessibility to patients. For more information about Orgenesis and its offerings, please visit their website at orgenesis.com.